NaviFUS Business Summary

NaviFUS Corp. (6872.TWO) is a clinical-stage medical technology firm specializing in the development of neuronavigation-guided focused ultrasound (FUS) systems for treating central nervous system (CNS) disorders. The company’s revenue model is primarily structured around strategic licensing agreements, clinical trial milestone payments, and the commercialization of its FDA-cleared NAVIRFA® surgical guidance platform, with future growth tied to the sale of its proprietary NaviFUS® hardware and single-use patient kits. Its core business segments focus on two therapeutic pillars: transient opening of the blood-brain barrier (BBB) to enhance the delivery of oncology and neurodegenerative drugs, and non-invasive neuromodulation for the treatment of drug-resistant epilepsy. NaviFUS differentiates itself by utilizing optical neuronavigation technology, which allows for precise targeting in an outpatient setting without the prohibitive costs and infrastructure of real-time MRI guidance. In a competitive landscape featuring Insightec, CarThera, and NeuroFUS, NaviFUS positions itself as a more accessible, portable, and cost-efficient alternative for precision neuro-intervention. The company’s foundation is rooted in the academic research of Dr. Hao-Li Liu, a renowned expert in therapeutic ultrasound from National Taiwan University who remains a pivotal scientific advisor. The current executive leadership is spearheaded by CEO Dr. Arthur (Lung-Hao) Hu, who possesses a robust track record in medical device development and international regulatory strategy from previous tenures at Medtronic and United Orthopedic. Chairman Dr. Chen-Hsin (Jen) Chen provides high-level governance, drawing on over 30 years of experience in drug development at Novartis and as the founder of Genovate Biotechnology. NaviFUS is supported by a sophisticated investor base that includes strategic backing from Genovate Biotechnology and various prominent Taiwanese venture capital firms. This leadership structure effectively bridges the gap between advanced ultrasonic engineering and the commercial rigor required to scale Class III medical devices in global markets.